

Supplementary Table 1 Clinical outcomes during 12 mo follow-up

Before administering of RTX (0 mo)			Administering RTX (3 mo)			of After administering RTX (6 mo)			of Follow-up (9 mo)			Follow-up (12 mo)			
Patient no.	24hU TP (g/d)	ALB (g/ L)	Scr (μmol /L)	24hU TP (g/d)	ALB (g/L)	Scr (μmol /L)	24hUT P (g/d)	ALB (g/L) (μmol/L)	Scr	24hUTP (g/d)	ALB (g/L)	Scr (μmol /L)	24hUT P (g/d)	ALB (g/L)	Scr (μmol /L)
1	15.2	13.9	97	12.7	22.7	110	2.3	25.1	64	1.2	28	86	1.88	44	66
2	7.1	29	78	5.7	35.3	71	3.6	36.9	72	3.2	37.1	82	2	36.2	83
3	17	16	202	13.2	18.6	150	9.9	24.3	93	4.1	26	85	4	29.9	116
4	6.7	26	142	-	-	-	-	-	-	-	-	-	-	-	-
5	5.7	35	84	3.07	41.5	67	1.03	45.1	64	0.2	43	63	0.09	49.5	90
6	1.8	37.4	78	0.88	40.3	79	1.3	42	82	0.3	42.3	70	0.6	40.1	75
7	3.5	32.5	90	2.05	35.8	99	1.8	35.1	69	0.15	43.6	84	0.27	44.1	88
8	15	26.9	91	6.8	26.1	89	6.2	29.4	70	4.3	35.3	85	0.9	41.4	82
9	1.3	35.8	125	0.78	38.8	114	0.64	39.1	111	0.5	39.4	121	0.175	42.2	124

